Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Operating Expenses: 2010-2016

Historic Other Operating Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 7 years, with Sep 2016 value amounting to -$3.8 million.

  • Arrowhead Pharmaceuticals' Other Operating Expenses rose 11.16% to $7.9 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$3.0 million, marking a year-over-year decrease of 107.06%. This contributed to the annual value of -$3.8 million for FY2016, which is 109.26% down from last year.
  • As of FY2016, Arrowhead Pharmaceuticals' Other Operating Expenses stood at -$3.8 million, which was down 109.26% from $41.2 million recorded in FY2015.
  • In the past 5 years, Arrowhead Pharmaceuticals' Other Operating Expenses ranged from a high of $41.2 million in FY2015 and a low of -$3.8 million during FY2016.
  • In the last 3 years, Arrowhead Pharmaceuticals' Other Operating Expenses had a median value of $24.4 million in 2014 and averaged $20.6 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Other Operating Expenses slumped by 115.12% in 2013 and then spiked by 1,817.67% in 2014.
  • Arrowhead Pharmaceuticals' Other Operating Expenses (Yearly) stood at $9.4 million in 2012, then slumped by 115.12% to -$1.4 million in 2013, then skyrocketed by 1,817.67% to $24.4 million in 2014, then surged by 68.55% to $41.2 million in 2015, then plummeted by 109.26% to -$3.8 million in 2016.